Chi-Chung Chan

664 total citations
24 papers, 414 citations indexed

About

Chi-Chung Chan is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Chi-Chung Chan has authored 24 papers receiving a total of 414 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Chi-Chung Chan's work include Lung Cancer Treatments and Mutations (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Lung Cancer Research Studies (3 papers). Chi-Chung Chan is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Lung Cancer Research Studies (3 papers). Chi-Chung Chan collaborates with scholars based in China, United States and Canada. Chi-Chung Chan's co-authors include Shu‐Hui Chen, Qingyang Gu, Hongye Sun, Qiang Xu, Douglas D. Fang, Mao Mao, Joycelyn Sim, Chor Sang Chim, Yok‐Lam Kwong and Martin Law and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Chi-Chung Chan

22 papers receiving 399 citations

Peers

Chi-Chung Chan
Ellen M. van der Aar Netherlands
H. Raftopoulos United States
Tokiko Nakamura Japan
Nancy Harold United States
Jean‐Michel Luccarini France
Hideo Tateishi Japan
Risu Na China
Stacey Mont United States
Ellen M. van der Aar Netherlands
Chi-Chung Chan
Citations per year, relative to Chi-Chung Chan Chi-Chung Chan (= 1×) peers Ellen M. van der Aar

Countries citing papers authored by Chi-Chung Chan

Since Specialization
Citations

This map shows the geographic impact of Chi-Chung Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chi-Chung Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chi-Chung Chan more than expected).

Fields of papers citing papers by Chi-Chung Chan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chi-Chung Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chi-Chung Chan. The network helps show where Chi-Chung Chan may publish in the future.

Co-authorship network of co-authors of Chi-Chung Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Chi-Chung Chan. A scholar is included among the top collaborators of Chi-Chung Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chi-Chung Chan. Chi-Chung Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dong, Jiaqiang, Charles Z. Ding, Lihong Hu, et al.. (2020). Design, syntheses and evaluations of novel indole derivatives as orally selective estrogen receptor degraders (SERD). Bioorganic & Medicinal Chemistry Letters. 30(22). 127601–127601. 13 indexed citations
2.
Wang, Jian, Qi Li, Yuanfeng Xia, et al.. (2020). Preclinical evaluation of SC0245, a small molecule inhibitor of ATR kinase.. Journal of Clinical Oncology. 38(15_suppl). e15642–e15642. 1 indexed citations
3.
Wang, Jianfei, Xiaohong Yu, Qingying Chen, et al.. (2020). Preclinical evaluation of SIM1803-1A, a small molecule Trk/ROS1 dual inhibitor for wild and mutate NTRK/ROS1 fusion solid malignancies.. Journal of Clinical Oncology. 38(15_suppl). e21663–e21663. 7 indexed citations
4.
Chen, Zhenxia, Deheng Sun, Yuanfeng Xia, et al.. (2020). Preclinical evaluation of WXSH0011, a selective small molecule dual inhibitor of FGFR/c-Met.. Journal of Clinical Oncology. 38(15_suppl). e15641–e15641. 1 indexed citations
5.
Li, Qi, et al.. (2020). Preclinical evaluation of SC0191, a small molecule inhibitor of Wee1 kinase.. Journal of Clinical Oncology. 38(15_suppl). e15637–e15637. 8 indexed citations
6.
Li, Jin, Ye Guo, Junli Xue, et al.. (2020). First-in-human (FIH) phase I study of GST-HG161, a potent and highly selective c-met inhibitor, in patients with advanced solid tumor.. Journal of Clinical Oncology. 38(15_suppl). e16126–e16126. 1 indexed citations
7.
Wu, Lingyun, Hanyu Yang, Lele Zhao, et al.. (2019). Abstract 4714: Preclinical evaluation of a novel LSD1 inhibitor SYHA1807 for the treatment of small cell lung cancer. Cancer Research. 79(13_Supplement). 4714–4714. 3 indexed citations
8.
Zhao, Rong, Fusheng Zhou, Jiong Lan, et al.. (2019). Abstract 3072: GFH018, a novel TGF-βRI inhibitor, for the treatment of advanced solid tumors. Cancer Research. 79(13_Supplement). 3072–3072. 3 indexed citations
9.
Zhang, Xiquan, Ling Yang, Xin Tian, et al.. (2019). Abstract 1320: Preclinical evaluation of TQB3804, a potent EGFR C797S inhibitor. 1320–1320. 10 indexed citations
10.
Wu, Chengde, Neng‐Yang Shih, Qi Li, et al.. (2018). Discovery of dimethyl pent-4-ynoic acid derivatives, as potent and orally bioavailable DGAT1 inhibitors that suppress body weight in diet-induced mouse obesity model. Bioorganic & Medicinal Chemistry Letters. 28(10). 1686–1692. 4 indexed citations
11.
Russell, John P., Anthony C. Johnson, Michael D. Gershon, et al.. (2018). Exploring the Potential of RET Kinase Inhibition for Irritable Bowel Syndrome: A Preclinical Investigation in Rodent Models of Colonic Hypersensitivity. Journal of Pharmacology and Experimental Therapeutics. 368(2). 299–307. 10 indexed citations
12.
Liang, Gui‐Bai, Dahai Wang, Shuhui Chen, et al.. (2018). Abstract 192: Preclinical evaluation of TQBWX220, a small-molecule inhibitor of IDO1. Cancer Research. 78(13_Supplement). 192–192. 2 indexed citations
13.
Fang, Douglas D., Bin Zhang, Qingyang Gu, et al.. (2014). HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib. Journal of Thoracic Oncology. 9(3). 285–294. 74 indexed citations
14.
15.
Fang, Douglas D., Yibo Gao, Qiang Xu, et al.. (2012). Abstract 2351: Identification of somatic mutations in esophageal squamous cell carcinoma and corresponding xenograft by next-generation sequencing. Cancer Research. 72(8_Supplement). 2351–2351.
16.
Chim, Chor Sang, Yok‐Lam Kwong, Chi-Chung Chan, et al.. (2005). Long-term Outcome of 231 Patients With Essential Thrombocythemia. Archives of Internal Medicine. 165(22). 2651–2651. 83 indexed citations
17.
Epstein, Solomon, Piet Geusens, Sophie Roy, et al.. (2005). Disintegration and Esophageal Irritation Profiles of Alendronate Formulations:Implications for Clinical Safety and Efficacy. 16 indexed citations
18.
Black, Shawn C., Christine Brideau, M. Cirino, et al.. (1998). Differential Effect of a Selective Cyclooxygenase-2 Inhibitor Versus Indomethacin on Renal Blood Flow in Conscious Volume-Depleted Dogs. Journal of Cardiovascular Pharmacology. 32(5). 686–694. 38 indexed citations
19.
Tousignant, Christine, et al.. (1993). Neurokinin receptor mediated plasma extravasation in guinea pig and rat airways: comparison of 125I-labelled human fibrinogen and 99mTc-labelIed human serum albumin as markers of leakage. Canadian Journal of Physiology and Pharmacology. 71(7). 506–511. 5 indexed citations
20.
Shiu, W., Nancy Leung, Michael Ho‐Yeung Chan, et al.. (1990). Hepatocellular Carcinoma in Hong Kong: Clinical Study on 340 Cases. Oncology. 47(3). 241–245. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ellen M. van der Aar Breakdown of academic impact, for papers by H. Raftopoulos Breakdown of academic impact, for papers by Tokiko Nakamura Breakdown of academic impact, for papers by Nancy Harold Breakdown of academic impact, for papers by Jean‐Michel Luccarini Breakdown of academic impact, for papers by Hideo Tateishi Breakdown of academic impact, for papers by Risu Na Breakdown of academic impact, for papers by Stacey Mont
Rankless by CCL
2026